These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Does pancreaticosplenectomy contribute to better survival?
    Author: Noguchi Y, Yamamoto Y, Morinaga S, Amano T, Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H.
    Journal: Hepatogastroenterology; 2002; 49(47):1436-40. PubMed ID: 12239961.
    Abstract:
    BACKGROUND/AIMS: This study was conducted to clarify the impact of pancreaticosplenectomy on the prognosis of patients with gastric carcinoma. METHODOLOGY: Two hundred and seventy-two patients who underwent total gastrectomy with distal pancreatectomy and splenectomy were retrospectively reviewed. RESULTS: Lymph node metastases at the splenic hilum (#10) and along the splenic artery (#11) occurred in 12.4% and 19.2% of cases, respectively. The 5-year survival rate of those without metastasis at #10 was 62.8%. Once nodal metastasis occurred, the prognosis became very poor; only 18.2% in those with a single positive node and 15.4% of those with two or more positive nodes at this location survived 5 years. Similar trends in survival were observed with respect to nodes at #11. When stratified by nodal status as currently determined by microscopic examination, pancreaticosplenectomy saved 4.5% of patients with positive nodes, but was insufficient in 17.3% of cases and was not necessary in the 78.2% of cases who were node negative at these locations. CONCLUSIONS: The data indicate that pancreaticosplenectomy can save some patients with positive nodes in these regions; however, the small survival benefit does not provide a basis for the general application of this highly morbid procedure. To further evaluate these results in a randomized study, selection of a subset of patients who are likely to have metastasis is the key.
    [Abstract] [Full Text] [Related] [New Search]